Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse.

For subsets of Duchenne muscular dystrophy (DMD) mutations, antisense oligoribonucleotide (AON)-mediated exon skipping has proven to be efficacious in restoring the expression of dystrophin protein. In the mdx murine model systemic delivery of AON, recognizing the splice donor of dystrophin exon 23, has shown proof of concept. Here, we show that using cationic polymethylmethacrylate (PMMA) (marked as T1) nanoparticles loaded with a low dose of 2'-O-methyl-phosphorothioate (2'OMePS) AON delivered by weekly intraperitoneal (IP) injection (0.9 mg/kg/week), could restore dystrophin expression in body-wide striated muscles. Delivery of an identical dose of naked AON did not result in detectable dystrophin expression. Transcription, western, and immunohistochemical analysis showed increased levels of dystrophin transcript and protein, and correct localization at the sarcolemma. This study shows that T1 nanoparticles have the capacity to bind and convoy AONs in body-wide muscle tissues and to reduce the dose required for dystrophin rescue. By immunofluorescence and electron microscopy studies, we highlighted the diffusion pathways of this compound. This nonviral approach may valuably improve the therapeutic usage of AONs in DMD as well as the delivery of RNA molecules with many implications in both basic research and medicine.

[1]  J. D. den Dunnen,et al.  Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. , 2006, Pharmacogenomics.

[2]  Hans P Merkle,et al.  Formulation aspects of biodegradable polymeric microspheres for antigen delivery. , 2005, Advanced drug delivery reviews.

[3]  C. Misquitta,et al.  The role of 3′-untranslated region (3′-UTR) mediated mRNA stability in cardiovascular pathophysiology , 2001, Molecular and Cellular Biochemistry.

[4]  M. Monsigny,et al.  Lactosylated polyethylenimine for gene transfer into airway epithelial cells: role of the sugar moiety in cell delivery and intracellular trafficking of the complexes , 2004, The journal of gene medicine.

[5]  G. van Ommen,et al.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. , 2007, RNA.

[6]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  H. Moulton,et al.  Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function , 2008, Human molecular genetics.

[8]  G. van Ommen,et al.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.

[9]  R. Vossen,et al.  Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J Kreuter,et al.  Evaluation of nanoparticles as drug-delivery systems. III: materials, stability, toxicity, possibilities of targeting, and use. , 1983, Pharmaceutica acta Helvetiae.

[11]  G. Altavilla,et al.  Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. , 2004, Vaccine.

[12]  G. Lutz,et al.  Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. , 2008, Human gene therapy.

[13]  A. Musarò,et al.  Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Ulmer,et al.  Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines , 2001, Journal of Virology.

[15]  S. Agrawal,et al.  Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. , 1992, Analytical biochemistry.

[16]  A. Rabinowitz,et al.  Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.

[17]  J. Löwer,et al.  High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines , 1991, AIDS.

[18]  A. Rabinowitz,et al.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[20]  E. Hoffman.  Skipping toward personalized molecular medicine. , 2007, The New England journal of medicine.

[21]  S. Tapscott,et al.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. , 2006, Human gene therapy.

[22]  J. Kreuter,et al.  New adjuvants on a polymethylmethacrylate base , 1976, Infection and immunity.

[23]  Giuseppe Altavilla,et al.  DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. , 2006, Vaccine.

[24]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[25]  A. Kabanov,et al.  Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents , 2000, Gene Therapy.

[26]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[27]  T. Prolla,et al.  Gene expression profiling studies of aging in cardiac and skeletal muscles. , 2005, Cardiovascular research.

[28]  D. Kohane,et al.  Polymers for intracellular delivery of nucleic acids , 2008 .

[29]  L. Barbu-Tudoran,et al.  Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[30]  P. Iversen,et al.  Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.

[31]  S. Wilton,et al.  Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. , 2003, Human molecular genetics.

[32]  Leaf Huang,et al.  Gene therapy progress and prospects: non-viral gene therapy by systemic delivery , 2006, Gene Therapy.

[33]  G. Lutz,et al.  Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice , 2008, BMC biotechnology.